GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mdechem Inc (OTCPK:MDKM) » Definitions » Capex-to-Revenue

Mdechem (Mdechem) Capex-to-Revenue : 0.00 (As of . 20)


View and export this data going back to . Start your Free Trial

What is Mdechem Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Mdechem's Capital Expenditure for the three months ended in . 20 was $0.00 Mil. Its Revenue for the three months ended in . 20 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Mdechem Capex-to-Revenue Historical Data

The historical data trend for Mdechem's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mdechem Capex-to-Revenue Chart

Mdechem Annual Data
Trend
Capex-to-Revenue

Mdechem Quarterly Data
Capex-to-Revenue

Competitive Comparison of Mdechem's Capex-to-Revenue

For the Biotechnology subindustry, Mdechem's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mdechem's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mdechem's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mdechem's Capex-to-Revenue falls into.



Mdechem Capex-to-Revenue Calculation

Mdechem's Capex-to-Revenue for the fiscal year that ended in . 20 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- () /
=N/A

Mdechem's Capex-to-Revenue for the quarter that ended in . 20 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- () /
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mdechem  (OTCPK:MDKM) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Mdechem Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mdechem's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mdechem (Mdechem) Business Description

Traded in Other Exchanges
N/A
Address
923 10th Street, Suite PMB101, Floresville, TX, USA, 78114
Mdechem Inc is a chemical manufacturing company. The company's product include Sandklene 950 a U.S. patented chemical solution that recovers hydrocarbons from tar/oil sands, Diesel Clean Power 500 an EPA verified technology making engines operate more effectively while using less fuel and reducing emission pollutants and Phosfamid patented chemical solution that inhibits metal corrosion and reduces friction.

Mdechem (Mdechem) Headlines

No Headlines